A Comprehensive Analysis of Birth Canal Injuries, Postpartum Hemorrhage, Disseminated Intravascular Coagulation, and Hemorrhagic Shock

1. Ali Afsha

2. Osmonova Gulnaz Zhenishbaevna

(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic

2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)

Abstract

Maternal mortality and severe maternal morbidity remain persistent global challenges, with obstetric hemorrhage and its associated systemic sequelae representing the leading cause of preventable intrapartum and postpartum maternal death worldwide. This comprehensive academic synthesis provides a thorough exploration of the continuum of acute obstetric crises, spanning soft tissue mechanical trauma to the birth canal, primary and secondary postpartum hemorrhage, acquired consumption coagulopathy in the form of disseminated intravascular coagulation, and terminal microvascular collapse characterized by hemorrhagic shock. Mechanical injuries to the birth canal—including perineal lacerations, obstetrical anal sphincter injuries, vaginal and cervical tears, puerperal hematomas, and uterine rupture—not only cause immediate vascular disruption but also impair physiological myometrial contractility. Uncontrolled hemorrhage rapidly activates a cascade of pathophysiological events governed by uterine atony, retained tissue, structural trauma, and acquired thrombin deficiency. As blood loss accelerates, the massive release of tissue factor from damaged tissue or retroplacental hematomas triggers disseminated intravascular coagulation, depleting fibrinogen, platelets, and key clotting factors while activating uncontrolled fibrinolysis. Uncorrected intravascular volume depletion ultimately culminates in hemorrhagic shock, driving profound tissue hypoperfusion, anaerobic metabolic shift, lactic acidosis, and the establishment of the lethal triad of trauma: hypothermia, acidosis, and coagulopathy. Contemporary management paradigms emphasize a shift from delayed, reactive care to rapid, multidisciplinary, protocol-driven damage control resuscitation. This includes early administration of antifibrinolytic therapy, goal-directed replacement of hemostatic components guided by viscoelastic point-of-care testing, balanced massive transfusion protocols, conservative and surgical vascular control, and invasive organ support. Understanding the intricate mechanical, biochemical, and physiological interactions across these entities is essential for maternal-fetal medicine specialists, obstetricians, anesthetists, and critical care physicians dedicated to reducing maternal mortality.

Introduction

Human parturition represents a remarkable physiological process that requires profound structural, hemodynamic, and metabolic adaptations. However, this process carries inherent risks of catastrophic vascular and mechanical complications that can rapidly convert a routine labor into a life-threatening obstetric emergency. Globally, obstetric hemorrhage remains the single largest contributor to maternal mortality, accounting for over twenty-seven percent of all maternal deaths annually according to epidemiological estimates from the World Health Organization. While the majority of these fatal outcomes occur in low- and middle-income countries due to resource limitations and delayed access to emergency obstetric care, severe maternal morbidity arising from hemorrhage and its downstream systemic consequences continues to rise even in high-resource healthcare settings. This persistent burden underscores the vital necessity of maintaining a deep, integrative understanding of the pathophysiological mechanisms, diagnostic pathways, and resuscitative protocols associated with peripartum vascular collapse.

The sequence of acute obstetric crises frequently follows a recognizable and devastating pathophysiological continuum. Soft tissue mechanical trauma to the birth canal, occurring spontaneously during precipitous or operative vaginal delivery or secondary to anatomical misalignments, serves as both a direct source of severe blood loss and a trigger for secondary functional abnormalities. Lacerations of the cervix, vagina, and perineum, alongside retroperitoneal or pelvic hematomas and complete uterine rupture, can bleed profusely due to the massive increase in uterine and pelvic blood flow during late pregnancy, which reaches approximately six hundred to eight hundred milliliters per minute. When these structural injuries coexist with or precipitate uterine atony—the failure of the myometrium to contract effectively following placental expulsion—the rate of maternal blood loss can rapidly exceed the physiological compensatory reserves of the maternal cardiovascular system, resulting in primary postpartum hemorrhage.

As intravascular volume depletes and tissue trauma accumulates, the cascade expands from localized vascular disruption to systemic hematological dysregulation. The continuous, unmitigated loss of blood, combined with the release of procoagulant substances such as tissue factor from ischemic uterine tissue, retroplacental clot, or amniotic fluid entry into maternal circulation, incites disseminated intravascular coagulation. This acquired syndrome represents an explosive, dysregulated activation of intravascular coagulation, causing widespread microvascular fibrin deposition, organ ischemia, and a subsequent, profound consumption of circulating platelets, fibrinogen, and prothrombin. The clinical state rapidly transitions from hypercoagulability to severe consumptive coagulopathy, marked by uncontrollable, generalized microvascular bleeding from surgical incisions, mucosal surfaces, and intravenous puncture sites.

Left unchecked, the confluence of massive volume loss, acute anemia, and severe consumption coagulopathy inevitably drives the patient into hemorrhagic shock. Hemorrhagic shock is characterized by a critical imbalance between systemic oxygen delivery and cellular oxygen demand, culminating in widespread tissue hypoperfusion, cellular hypoxia, anaerobic glycolysis, and intracellular metabolic acidosis. The progressive deterioration of microvascular perfusion triggers systemic inflammatory cascades, endothelial dysfunction, and capillary leak, leading to the lethal triad of hypothermia, metabolic acidosis, and coagulopathy. Each component of this triad exacerbates the others, creating a self-reinforcing cycle of cellular death, myocardial failure, and irreversible multi-organ dysfunction syndrome. Modern obstetric critical care demands a departure from historically reactive, piecemeal approaches in favor of early, standardized, protocolized interventions. This article reviews the pathophysiology, diagnostic criteria, and management strategies for birth canal injuries, postpartum hemorrhage, disseminated intravascular coagulation, and hemorrhagic shock, offering a unified, evidence-based approach to these life-threatening obstetric emergencies.

Methods

To synthesize a comprehensive, state-of-the-art review on traumatic, hemorrhagic, and coagulopathic emergencies in obstetrics, a rigorous literature search and content evaluation strategy was executed across major biomedical and academic databases, including PubMed, MEDLINE, Scopus, the Cochrane Database of Systematic Reviews, and Web of Science. The primary goal was to retrieve high-quality, peer-reviewed clinical studies, randomized controlled trials, systematic reviews, meta-analyses, and updated clinical practice guidelines published by major international health authorities and professional medical societies. Search terms were combined using Boolean logic operators and encompassed a broad range of descriptors, including soft tissue birth trauma, perineal laceration repair, obstetrical anal sphincter injuries, pelvic hematoma, uterine rupture, primary postpartum hemorrhage, uterine atony, 4 Ts of postpartum hemorrhage, tranexamic acid, WOMAN trial, intrauterine balloon tamponade, compression sutures, disseminated intravascular coagulation in pregnancy, amniotic fluid embolism, placental abruption, viscoelastic hemostatic assays, thromboelastography, rotational thromboelastometry, damage control resuscitation, massive transfusion protocol, and obstetric hemorrhagic shock.

The inclusion criteria prioritized peer-reviewed articles that provided fundamental physiological insights, validated clinical diagnostic algorithms, or established evidence-based management protocols. Key emphasis was directed toward landmark clinical trials, such as the World Maternal Antifibrinolytic trial, as well as official guidelines issued by the American College of Obstetricians and Gynecologists, the Royal College of Obstetricians and Gynaecologists, the World Health Organization, the International Federation of Gynecology and Obstetrics, and the International Liaison Committee on Resuscitation. Studies addressing point-of-care diagnostic innovations, such as rotational thromboelastometry and viscoelastic testing in obstetric critical care, were carefully analyzed to ensure the incorporation of contemporary advances in hemostatic monitoring.

Data extracted from the identified literature were categorized into four primary thematic domains corresponding to the core clinical topics: mechanical birth canal injuries, postpartum hemorrhage, disseminated intravascular coagulation, and hemorrhagic shock. Within each domain, information was critically evaluated for mechanistic plausibility, diagnostic accuracy, therapeutic efficacy, and clinical safety profiles. The synthesized data were then formatted into an integrated narrative text structured according to the classic academic framework. To maintain an authoritative tone suitable for advanced medical study, all synthesized information was structured into continuous, densely detailed narrative paragraphs.

Results and Discussion

Section 1: Injuries to the Birth Canal

Mechanical trauma to the soft tissues of the birth canal represents a common and clinically significant cause of maternal morbidity during parturition. The passage of the fetus through the pelvic canal subjects the maternal perineum, vagina, cervix, and uterine wall to extreme mechanical forces involving compression, shearing, and stretching. Under physiological conditions, the elastic connective tissue and vascular structures adapt to these forces; however, when mechanical stress exceeds the tensile strength of the maternal tissues, anatomical disruption occurs. The risk of birth canal trauma is heightened by several intrapartum factors, including fetal macrosomia, precipitous labor, malposition such as persistent occiput posterior presentation, instrumental vaginal delivery utilizing vacuum extractors or obstetrical forceps, shoulder dystocia interventions, prolonged second stage of labor, and a history of previous perineal scarring or tissue vulnerability. Recognizing and accurately classifying these injuries is necessary, as uncorrected soft tissue trauma can lead to severe hemorrhage, pelvic floor dysfunction, chronic pain, and long-term disruptions in bowel and bladder continence.

Perineal lacerations are the most frequent form of soft tissue trauma encountered in obstetrics and are anatomically categorized into four distinct degrees based on the depth and specific structures involved. First-degree lacerations are superficial injuries confined strictly to the perineal skin and the vaginal mucosa, leaving the underlying fascial and muscular structures intact. Second-degree lacerations extend deeper to involve the skin, vaginal mucosa, and the muscles of the perineal body, specifically the bulbospongiosus, superficial transverse perineal, and occasionally fibers of the pubococcygeus muscle, while carefully sparing the anal sphincter complex. Third-degree lacerations represent more extensive structural damage, extending through the perineal body to disrupt the anal sphincter complex. Third-degree injuries are further subclassified into grade three-a, involving less than fifty percent of the external anal sphincter thickness; grade three-b, involving greater than fifty percent of the external anal sphincter thickness; and grade three-c, where both the external anal sphincter and the internal anal sphincter are completely torn. Fourth-degree lacerations represent the most severe spectrum of perineal trauma, involving complete disruption of the external and internal anal sphincters alongside laceration of the anal epithelium, thereby exposing the anorectal lumen.

The repair of obstetrical anal sphincter injuries requires precise surgical technique, meticulous anatomical layer-by-layer approximation, and strict aseptic conditions, ideally performed in an operating room with adequate lighting, regional or general anesthesia, and appropriate surgical assistance. For fourth-degree tears, the rectal mucosa is repaired first using fine, continuous, or interrupted absorbable sutures, such as 4-0 polyglactin, taking care not to penetrate the lumen with knots tied within the submucosa to minimize the risk of rectovaginal fistula formation. The internal anal sphincter, which provides the majority of resting anal tone and is visible as a pale, fibrous muscular layer, is identified and repaired separately using interrupted or mattress sutures. The external anal sphincter can then be approximated using either an end-to-end technique or an overlap technique, depending on the operator's expertise and the precise nature of the muscular tear, utilizing delayed-absorbable 2-0 or 3-0 monofilament or braided sutures. Following sphincter reconstruction, the perineal body musculature, vaginal epithelium, and perineal skin are reapproximated in a continuous, tension-free fashion. Postoperative management of severe perineal trauma focuses on preventing wound breakdown, infection, and constipation, incorporating broad-spectrum prophylactic antibiotics, stool softeners, local hygienic care, and structured pelvic floor physical therapy.

Vaginal and cervical lacerations present unique diagnostic and therapeutic challenges due to their potential for occult, massive arterial bleeding. Vaginal lacerations frequently occur along the lateral sulci or upper third of the vagina, often secondary to instrumental deliveries where forceps blades or vacuum cups exert rotational shearing forces against the vaginal wall. High vaginal tears can extend superiorly into the lateral fornices, occasionally damaging the vaginal branches of the uterine artery, which can result in rapid intra-vaginal or retroperitoneal hemorrhage. Cervical lacerations are particularly common following rapid fetal expulsion through an incompletely dilated cervix or following manual dilation attempts. Cervical tears usually occur laterally at the three o'clock and nine o'clock positions, corresponding to the primary vascular entry points of the uterine arteries. A thorough visual examination of the entire cervix using ring forceps to systematically walk around the circumferential margin is mandatory in any patient presenting with persistent, bright red vaginal bleeding despite a firmly contracted uterus. Surgical repair of cervical lacerations requires high-level exposure, assistant retraction, and placement of interrupted absorbable sutures starting superior to the apex of the tear to secure retraction of retracted, bleeding vessels.

Puerperal hematomas represent a insidious form of birth canal injury where vascular disruption occurs beneath an intact epithelial or fascial layer, leading to localized or spreading accumulations of blood. These hematomas are classified anatomically into vulvar, vaginal, vulvovaginal, and retroperitoneal or broad ligament hematomas. Vulvar hematomas typically arise from rupture of branches of the internal pudendal artery, specifically the inferior rectal, perineal, or posterior labial arteries, and are bounded by the rigid fascial layers of the perineum. Patients present with severe, agonizing, pressure-like pelvic pain out of proportion to clinical findings, accompanied by a tense, exquisite, purple, expanding mass in the labia or perineum. Vaginal hematomas originate from damage to the vaginal mucosal or submucosal venous plexuses and can expand silently, dissecting through the rectovaginal septum to cause rectal pressure, tenesmus, and urinary retention. Retroperitoneal hematomas are the most dangerous, occurring when damage to the uterine artery branches or pelvic venous plexuses dissects superiorly above the pelvic fascia into the broad ligament or retroperitoneal space. These retroperitoneal collections can accommodate several liters of blood without external bleeding, manifesting primarily as unexplained hemodynamic collapse, flank ecchymosis, and falling hematocrit.

Small, non-expanding vulvar or vaginal hematomas under five centimeters in diameter can often be managed conservatively with ice packs, compression, bed rest, strict analgesia, and close monitoring of vital signs and serial complete blood counts. However, rapidly expanding or large hematomas require prompt surgical intervention. The hematoma cavity must be widely incised, deep clots evacuated, bleeding vessels identified and ligated, and the dead space obliterated using multiple continuous or figure-of-eight absorbable sutures, followed by vaginal packing and placement of a Foley catheter to prevent urinary retention. In cases where diffuse tissue oozing prevents clear surgical vessel identification, or in the setting of deep retroperitoneal dissection, pelvic angiography with selective transcatheter arterial embolization of the internal iliac or uterine artery branches serves as a life-saving, minimally invasive procedure to halt occult arterial bleeding.

Uterine rupture represents a catastrophic, life-threatening obstetric event defined as a complete, full-thickness disruption of the myometrium, including the overlying visceral peritoneum, resulting in direct communication between the uterine cavity and the peritoneal cavity. It must be distinguished from uterine dehiscence, which involves incomplete myometrial separation with intact serosa, often asymptomatic and discovered incidentally during repeat cesarean delivery. The predominant risk factor for uterine rupture is the presence of a pre-existing uterine scar, most commonly from a previous low-transverse or classical cesarean delivery, or prior transmural myomectomy. Other contributing factors include obstructed labor, cephalopelvic disproportion, grand multiparity, excessive or unmonitored oxytocin administration, uterine hyperstimulation, internal podalic version, and trauma. The classic clinical presentation includes sudden, severe intra-abdominal pain, sharp breakthrough pain despite adequate regional anesthesia, cessation of uterine contractions, loss of fetal station on vaginal examination, vaginal bleeding, and rapid maternal hemodynamic instability. However, the most consistent and early sign of uterine rupture is an abnormal fetal heart rate pattern, typically profound, persistent fetal bradycardia or severe variable decelerations caused by acute fetal hypoxia following placental detachment or cord prolapse into the abdominal cavity. Emergency management of uterine rupture requires immediate surgical intervention via exploratory laparotomy, concurrent maternal stabilization and blood resuscitation, rapid delivery of the fetus, and definitive surgical repair of the uterine defect or, in cases of extensive starry tears or uncontrollable hemorrhage, emergent subtotal or total peripartum hysterectomy.

Section 2: Postpartum Hemorrhage

Postpartum hemorrhage remains the predominant cause of acute maternal mortality worldwide, representing a clinical emergency that demands immediate recognition, systematic assessment, and aggressive, protocolized management. Historically, postpartum hemorrhage was defined qualitatively as an estimated blood loss exceeding five hundred milliliters following a vaginal delivery, or exceeding one thousand milliliters following a cesarean delivery. However, subjective visual estimation of blood loss is notoriously inaccurate, consistently underestimating actual maternal volume loss by thirty to fifty percent due to blood mixing with amniotic fluid, saturation of surgical drapes, and concealment within the uterine cavity or retroperitoneum. To address these diagnostic deficiencies, modern international clinical consensus guidelines have redefined primary postpartum hemorrhage as a cumulative blood loss equal to or exceeding one thousand milliliters, or blood loss accompanied by signs or symptoms of hypovolemia within twenty-four hours following the birth process, regardless of the route of delivery. Secondary, or late, postpartum hemorrhage is defined as excessive bleeding occurring between twenty-four hours and twelve weeks postpartum, most frequently caused by retained placental fragments, subinvolution of the placental site, or endometritis.

The underlying etiologies of primary postpartum hemorrhage are universally categorized according to the established framework of the "4 Ts": Tone, Tissue, Trauma, and Thrombin. Uterine atony, representing the "Tone" category, is the single most common cause of postpartum hemorrhage, accounting for seventy to eighty percent of all cases. Following the detachment of the placenta, physiological hemostasis depends primarily on the powerful, sustained contraction and retraction of the interlacing myometrial smooth muscle fibers. These contracting muscle fibers act as physiological "living ligatures," mechanically compressing and occluding the low-resistance spiral arteries and venous sinuses that supply the placental site. Factors that interfere with effective post-delivery myometrial contraction include uterine overdistension from multifetal gestation, polyhydramnios, or fetal macrosomia; myometrial exhaustion resulting from prolonged, augmented labor or rapid precipitous labor; intra-amniotic infection or chorioamnionitis; high concentrations of halogenated volatile anesthetic agents; uterine leiomyomas; and grand multiparity.

The second category, "Tissue," accounts for approximately ten percent of hemorrhage cases and involves the retention of placental fragments, succenturiate lobes, or blood clots within the uterine cavity, which physically prevents complete myometrial contraction and closure of the retroplacental vascular bed. This category also encompasses the placenta accreta spectrum, a complex pathological condition characterized by abnormal, invasive adherence of the chorionic villi directly to or through the myometrium due to a deficiency of the intervening decidua basalis, frequently associated with prior cesarean uterine scars. The third category, "Trauma," includes the soft tissue lacerations, puerperal hematomas, and uterine rupture detailed previously, as well as acute uterine inversion, a rare obstetric emergency where the uterine fundal wall collapses inward and prolapses through the cervix, causing massive hemorrhage and severe neurogenic shock from peritoneal traction. The final category, "Thrombin," encompasses pre-existing or acquired coagulopathies, such as von Willebrand disease, immune thrombocytopenia, severe preeclampsia with HELLP syndrome, placental abruption, amniotic fluid embolism, and advanced sepsis, which impair clot formation at the site of vascular injury.

The clinical management of primary postpartum hemorrhage requires a rapid, multidisciplinary, stepwise algorithm executed simultaneously alongside active maternal hemodynamic resuscitation. The immediate physical management of suspected uterine atony begins with aggressive bimanual uterine compression and uterine massage. The clinician places one hand in the vagina, forming a fist in the anterior vaginal fornix, while the opposite hand depresses the abdominal wall over the posterior aspect of the uterine fundus, mechanically compressing the uterine body and stimulating endogenous myometrial contractility. Concurrently, supplemental high-flow oxygen is administered, continuous physiological monitoring is established, and two large-bore peripheral intravenous cannulae (14-gauge or 16-gauge) are inserted to facilitate rapid fluid and blood administration, while sending emergency blood samples for crossmatching, full blood count, coagulation profile, fibrinogen concentration, and arterial blood gas analysis.

Pharmacological therapy represents the primary medical intervention for uterine atony and must be administered sequentially and rapidly. Oxytocin is the universally recognized first-line uterotonic agent for both the prevention and treatment of postpartum hemorrhage. It acts selectively on G-protein-coupled oxytocin receptors on myometrial cell membranes, opening voltage-gated calcium channels to stimulate rhythmic myometrial contractions. Oxytocin is administered as a continuous intravenous infusion of ten to forty units diluted in one liter of crystalloid solution; rapid, undiluted intravenous bolus administration of oxytocin must be strictly avoided, as it can induce acute, profound systemic vasodilation, hypotension, cardiac arrhythmias, and collapse. When uterine atony persists despite oxytocin administration, secondary uterotonic medications must be deployed immediately. Methylergonovine or ergometrine, smooth muscle ergot alkaloids that induce sustained, tetanic myometrial contractions, are administered intramuscularly at a dose of zero point two milligrams. However, ergot alkaloids induce widespread peripheral vasoconstriction and are strictly contraindicated in patients with hypertensive disorders, including preeclampsia, chronic hypertension, and ischemic heart disease.

Carboprost tromethamine, a synthetic prostaglandin F2-alpha analogue, is another highly potent second-line uterotonic administered as a zero point two five milligram deep intramuscular or intramyometrial injection, repeatable every fifteen to ninety minutes up to a maximum dose of two milligrams. Carboprost acts by increasing intracellular calcium concentrations within smooth muscle cells, but its intense bronchoconstrictive and pulmonary vascular vasoconstrictive properties make it strictly contraindicated in patients with reactive airway disease or bronchial asthma. Misoprostol, a synthetic prostaglandin E1 analogue, is an effective alternative or adjunct uterotonic, particularly in resource-limited settings, due to its stability at room temperature and ease of administration. It is typically administered sublingually or rectally at a dose of six hundred to eight hundred micrograms, though its onset of action is slower than parenteral agents, and it frequently causes transient hyperthermia, shivering, and diarrhea. Carbetocin, a long-acting synthetic oxytocin analogue with a half-life four to five times longer than natural oxytocin, is increasingly utilized as a single-dose alternative in intravenous or intramuscular formulations to maintain prolonged uterine tone.

A major advance in the early medical management of postpartum hemorrhage is the routine, early administration of the antifibrinolytic agent tranexamic acid. Tranexamic acid is a synthetic lysine analogue that competitively inhibits the activation of plasminogen to plasmin, thereby preventing the enzymatic degradation of fibrin clots and stabilizing microvascular thrombi at the placental site and traumatized soft tissues. The definitive evidence for its efficacy was established by the landmark World Maternal Antifibrinolytic trial, a prospective, international, double-blind, randomized controlled trial involving over twenty thousand women with postpartum hemorrhage. The trial demonstrated that early administration of intravenous tranexamic acid within three hours of birth significantly reduced maternal death due to bleeding by over thirty percent without increasing the risk of thromboembolic events, such as deep vein thrombosis, pulmonary embolism, or stroke. Based on these findings, international guidelines mandate the administration of one gram of tranexamic acid intravenously in one hundred milliliters of normal saline over ten minutes as soon as postpartum hemorrhage is diagnosed, with a second one-gram dose administered if bleeding continues after thirty minutes or recurs within twenty-four hours.

When medical and pharmacological interventions fail to achieve satisfactory hemostasis, conservative surgical and endovascular procedures are deployed before considering definitive hysterectomy. Intrauterine balloon tamponade represents a minimally invasive, highly effective mechanical option for controlling persistent bleeding from uterine atony or lower uterine segment placental site bleeding. Devices such as the Bakri balloon or dual-balloon catheters are inserted through the cervix into the uterine cavity under ultrasound guidance and inflated with three hundred to five hundred milliliters of sterile warm saline. The balloon exerts uniform, retrograde hydrostatic pressure against the internal uterine walls and retroplacental vascular plexus, exceeding maternal systemic capillary pressure and physically tamponading microvascular bleeding. Alternatively, vacuum-induced hemorrhage control systems, such as the Jada device, utilize low-level negative intra-uterine pressure to physically collapse the uterine cavity, forcing the myometrium into a sustained, physiological contractile state.

In refractory cases, open surgical interventions during laparotomy offer targeted mechanical control. Uterine compression sutures, most notably the B-Lynch technique or its variants like the Hayman and Pereira sutures, involve wrapping continuous, heavy, absorbable monofilament sutures, such as 1-0 or 2-0 chromic gut or polydioxanone, longitudinally around the uterine wall from the lower segment to the fundus. When pulled taut and tied, these sutures mechanically compress the anterior and posterior uterine walls together, mimicking continuous, powerful bimanual compression and occluding intramyometrial vascular channels while preserving uterine and reproductive integrity. If bleeding persists, stepwise surgical devascularization can be executed, involving bilateral ligation of the uterine arteries at the level of the internal os, followed by ligation of the ovarian artery anastomotic branches, and ultimately bilateral ligation of the internal iliac (hypogastric) arteries. Ligation of the internal iliac arteries reduces pelvic arterial pulse pressure by up to eighty-five percent, transforming a high-pressure arterial system into a low-pressure venous-like circuit that facilitates stable clot formation. Selective transcatheter arterial embolization by interventional radiology represents an equally effective endovascular alternative in hemodynamically stable patients. When all conservative medical, mechanical, and surgical measures fail, or in cases of extensive placenta accreta spectrum or irreversible uterine rupture, peripartum emergency hysterectomy remains the definitive, life-saving surgical procedure to halt exsanguination.

Section 3: Disseminated Intravascular Coagulation (DIC) in Obstetrics

Disseminated intravascular coagulation is an acquired, life-threatening clinicopathological syndrome characterized by the systemic, uncontrolled activation of the coagulation cascade, leading to widespread microvascular thrombosis, consumption of endogenous procoagulant factors and platelets, and secondary hyperfibrinolysis. In obstetrics, disseminated intravascular coagulation represents a secondary complication driven by an underlying primary clinical insult that releases massive quantities of procoagulant materials into the maternal vascular bed. The unique physiology of pregnancy, which represents a baseline hypercoagulable state characterized by increased concentrations of fibrinogen and clotting factors VII, VIII, X, and von Willebrand factor alongside suppressed fibrinolysis, creates a system exceptionally prone to severe coagulopathic dysregulation when provoked by acute tissue trauma or endothelial damage.

The pathophysiological hallmark of obstetric disseminated intravascular coagulation is the massive, unchecked release of tissue factor, a transmembrane glycoprotein, into the maternal systemic circulation. Tissue factor binds with high affinity to circulating factor VIIa, forming the extrinsic tenase complex, which activates factor X to factor Xa. Factor Xa subsequently converts prothrombin into thrombin, triggering a burst of systemic thrombin generation that overwhelms natural circulating anticoagulant mechanisms, including antithrombin, protein C, and tissue factor pathway inhibitor. The widespread circulating thrombin converts fibrinogen to fibrin monomers, which polymerize and form microvascular microthrombi throughout the microcirculation of vital organs, including the kidneys, lungs, liver, and brain. This widespread microvascular thrombosis leads to tissue ischemia, red blood cell fragmentation causing microangiopathic hemolytic anemia, and multi-organ dysfunction.

Concurrently, this systemic clotting process consumes circulating blood platelets, fibrinogen, prothrombin, factor V, and factor VIII at a rate far exceeding hepatic synthesis and bone marrow megakaryopoiesis. This rapid exhaustion of essential clotting components converts the initial hypercoagulable, thrombotic state into a consumptive, hypocoagulable state. Compounding this consumptive state is the secondary activation of the fibrinolytic system. In response to widespread microvascular fibrin deposition, vascular endothelial cells release massive quantities of tissue plasminogen activator, converting plasminogen into plasmin. Plasmin cleaves crosslinked fibrin into circulating fibrin degradation products, including D-dimers. Elevated levels of circulating fibrin degradation products exert a potent direct anti-hemostatic effect, competitively inhibiting thrombin, impairing normal fibrin polymerization, and causing profound platelet dysfunction. The ultimate clinical manifestation is a catastrophic bleeding disorder characterized by generalized, uninhibited microvascular oozing from mucous membranes, surgical incisions, episiotomy sites, intravenous access sites, and the placental bed.

Obstetric etiologies of disseminated intravascular coagulation are varied, but several specific clinical entities account for the vast majority of cases. Placental abruption, the premature separation of a normally implanted placenta from the uterine wall prior to delivery, is the single most common cause of severe consumptive coagulopathy in obstetrics. In placental abruption, the retroplacental hematoma generates immense mechanical pressure, forcing high concentrations of tissue-factor-rich decidual and placental thromboplastins directly into the maternal venous sinuses under high pressure. Amniotic fluid embolism represents another catastrophic driver of hyperacute disseminated intravascular coagulation. This condition occurs when amniotic fluid containing fetal squames, mucin, lanugo, and procoagulant tissue factor enters the maternal circulation through disrupted endocervical veins or placental implantation sites, triggering acute pulmonary vascular vasospasm, severe right heart collapse, anaphylactoid inflammatory response, and explosive, hyperfibrinolytic coagulopathy within minutes.

Other prominent etiologies include severe preeclampsia and HELLP syndrome, where widespread endothelial cell damage promotes platelet aggregation, systemic microvascular thrombosis, and secondary factor consumption. Severe intra-amniotic infection, puerperal sepsis, and septic abortion drive disseminated intravascular coagulation through the actions of circulating bacterial endotoxins and pro-inflammatory cytokines, such as tumor necrosis factor-alpha and interleukin-1, which upregulate tissue factor expression on vascular monocytes and endothelial cells while downregulating endothelial protein C receptors. Prolonged retention of a dead fetus in utero beyond three to four weeks, known as retained dead fetus syndrome, allows slow, continuous leakage of necrotic tissue thromboplastins across the placenta into maternal circulation, inducing a subacute, insidious form of consumptive coagulopathy.

Laboratory evaluation and scoring systems are critical for confirming the diagnosis of disseminated intravascular coagulation and guiding replacement therapy. Standard laboratory findings in overt disseminated intravascular coagulation include marked hypofibrinogenemia, severe thrombocytopenia with platelet counts dropping below fifty thousand per microliter, marked prolongation of both prothrombin time and activated partial thromboplastin time, and elevated levels of circulating D-dimer and fibrin degradation products. In non-pregnant individuals, a plasma fibrinogen concentration of one hundred and fifty to two hundred milligrams per deciliter is considered normal; however, because normal physiological pregnancy elevates baseline plasma fibrinogen to four hundred to six hundred milligrams per deciliter, a fibrinogen level falling below two hundred milligrams per deciliter in a pregnant or immediate postpartum patient represents severe, pathological hypofibrinogenemia and serves as a sensitive indicator of impending coagulopathic collapse. Diagnostic scoring frameworks, such as the International Society on Thrombosis and Haemostasis overt disseminated intravascular coagulation score adapted for pregnancy, synthesize these laboratory parameters to establish a definitive diagnosis.

In modern critical care obstetrics, standard static coagulation laboratory tests are increasingly supplemented or replaced by point-of-care Viscoelastic Hemostatic Assays, specifically Thromboelastography and Rotational Thromboelastometry. Standard coagulation panels measure only the initiation phase of clot formation in cell-free plasma and typically require forty-five to sixty minutes for processing, rendering them ill-suited for real-time monitoring during rapid hemorrhage. In contrast, viscoelastic assays utilize whole blood to evaluate the complete functional dynamics of hemostasis in real time, capturing clot initiation, kinetic propagation, maximum clot firmness and elasticity, and rate of fibrinolysis within ten to fifteen minutes. Key parameters measured by thromboelastography include the R-value, reflecting clotting factor availability; the K-value and alpha angle, reflecting fibrinogen concentration and speed of clot formation; the Maximum Amplitude, reflecting combined platelet count, platelet function, and fibrinogen contribution; and the LY30, quantifying the percentage of clot lysis thirty minutes post-maximum amplitude to detect hyperfibrinolysis.

Similarly, rotational thromboelastometry utilizes distinct diagnostic channels to isolate specific coagulation components: the EXTEM channel evaluates the extrinsic pathway using tissue factor activation; the INTEM channel evaluates the intrinsic pathway; the FIBTEM channel incorporates a potent platelet inhibitor, cytochalasin D, to isolate the specific functional contribution of fibrinogen to clot firmness; and the APTEM channel utilizes a fibrinolytic inhibitor, such as aprotinin or tranexamic acid, to confirm hyperfibrinolysis when compared directly to EXTEM. In the setting of obstetric disseminated intravascular coagulation, rotational thromboelastometry can rapidly identify severe functional hypofibrinogenemia via a low FIBTEM maximum clot firmness under seven to ten millimeters, severe thrombocytopenia via a low EXTEM maximum clot firmness with a preserved FIBTEM trace, or fulminant hyperfibrinolysis via rapid breakdown of the EXTEM clot profile. This real-time diagnostic capability enables clinicians to execute targeted, goal-directed replacement therapy rather than relying on empirical, unguided blood administration.

The definitive treatment of obstetric disseminated intravascular coagulation relies on two parallel clinical imperatives: the urgent removal or resolution of the underlying obstetric cause, and aggressive, goal-directed replacement of specific consumed hemostatic components. Correcting the primary underlying etiology—such as performing rapid delivery in placental abruption, surgically controlling uterine bleeding in atony, or evacuating infected tissue in septic abortion—removes the continuous release of tissue factor driving intravascular clotting. Simultaneously, targeted component therapy must be initiated to maintain adequate hemostatic function. Fibrinogen replacement is the cornerstone of coagulopathic resuscitation in obstetrics. Fibrinogen can be restored using cryoprecipitate or purified, virus-inactivated human fibrinogen concentrates. Cryoprecipitate is a concentrated plasma fraction rich in fibrinogen, factor VIII, factor XIII, and von Willebrand factor; ten units of cryoprecipitate typically raise the circulating plasma fibrinogen level by approximately fifty to one hundred milligrams per deciliter. Purified fibrinogen concentrate offers distinct advantages over cryoprecipitate, as it can be rapidly reconstituted at the bedside without time-consuming thawing procedures, carries a lower volume load, and undergoes rigorous viral inactivation. The therapeutic goal during active obstetric hemorrhage is to maintain plasma fibrinogen levels strictly above two hundred milligrams per deciliter, or maintain a FIBTEM maximum clot firmness above twelve millimeters.

Additional component therapies are administered based on specific clinical laboratory thresholds and viscoelastic parameters. Fresh frozen plasma contains all soluble plasma coagulation factors in physiological concentrations and is administered at a dose of fifteen to twenty milliliters per kilogram when the prothrombin time or activated partial thromboplastin time exceeds one point five times the normal laboratory control value, or when the rotational thromboelastometry clotting time in EXTEM or INTEM channels is significantly prolonged. Prothrombin complex concentrates, containing purified vitamin K-dependent clotting factors, can be considered as a rapid-acting, low-volume alternative to fresh frozen plasma in select critical situations, though their use requires cautious dosing to avoid paradoxical thrombosis. Platelet concentrates are transfused to maintain a circulating platelet count strictly above fifty thousand per microliter during active hemorrhage, or above one hundred thousand per microliter in the presence of ongoing severe microvascular bleeding or neurosurgical/epidural interventions. The administration of antifibrinolytics, specifically tranexamic acid, is crucial in the hyperfibrinolytic phase of disseminated intravascular coagulation to arrest plasmin-mediated clot breakdown, but must be paired with active factor and platelet replacement.

Section 4: Hemorrhagic Shock

Hemorrhagic shock in obstetrics is an acute, life-threatening cardiovascular crisis characterized by a severe reduction in circulating intravascular blood volume secondary to acute blood loss, culminating in systemic microvascular tissue hypoperfusion, cellular hypoxia, metabolic failure, and multi-organ breakdown. The maternal cardiovascular system undergoes substantial adaptive expansion during pregnancy, expanding total plasma volume by forty to fifty percent and red cell mass by twenty to thirty percent, producing a total circulating blood volume of approximately six to seven liters at term. While this hypervolemic adaptation provides a physiological buffer that allows healthy pregnant women to lose up to one thousand to fifteen hundred milliliters of blood without exhibiting early clinical signs of hemodynamic compromise, it can also dangerously obscure the early diagnosis of severe shock. By the time classical clinical signs of shock emerge—such as profound hypotension, severe tachycardia, cool clammy extremities, oliguria, and altered mental status—the patient has frequently lost over thirty to forty percent of their effective circulating volume and is on the verge of sudden cardiovascular collapse.

The hemodynamic pathophysiology of hemorrhagic shock progresses through three distinct, overlapping phases: compensated shock, decompensated shock, and irreversible shock. In compensated shock, corresponding to an acute blood volume loss of fifteen to thirty percent (approximately one thousand to fifteen hundred milliliters), the body activates powerful neuroendocrine compensatory mechanisms to preserve central systemic perfusion. Arterial baroreceptor desensitization triggers a surge in sympathetic nervous system discharge, stimulating massive release of endogenous catecholamines, epinephrine, and norepinephrine, alongside activation of the renin-angiotensin-aldosterone axis and vasopressin release from the posterior pituitary gland. These hormonal shifts induce intense, selective peripheral and visceral vasoconstriction, shifting blood flow away from non-essential capillary beds such as the skin, skeletal muscle, gastrointestinal tract, and uterus, toward vital central organs including the heart, brain, and adrenal glands. Consequently, the maternal mean arterial blood pressure and cardiac output remain within near-normal limits, manifested clinically only by mild tachycardia, narrow pulse pressure, mild tachypnea, and cool extremities. However, uterine blood flow drops precipitously during compensated maternal shock due to profound uterine arterial vasoconstriction, resulting in acute fetal distress and late decelerations on electronic fetal monitoring long before maternal systemic hypotension becomes apparent.

When blood loss accelerates to thirty to forty percent of total circulating volume (approximately fifteen hundred to two thousand milliliters), compensatory mechanisms become overwhelmed, driving the patient into decompensated shock. In this phase, widespread arteriolar vasospasm fails to maintain adequate cardiac preload and stroke volume, leading to a precipitous drop in cardiac output and systemic mean arterial pressure. Microvascular perfusion to peripheral tissues declines severely, starving cells of oxygen and glucose. Lacking oxygen, cellular metabolism shifts from aerobic oxidative phosphorylation to inefficient anaerobic glycolysis, producing minimal adenosine triphosphate and massive quantities of lactic acid. Lactic acidosis impairs cellular function and damages membrane-bound sodium-potassium adenosine triphosphatase pumps. As cellular pumps fail, sodium and water rush into cells, causing systemic cellular swelling, lysosomal membrane disruption, release of intracellular proteolytic enzymes, and cellular death. Prolonged tissue hypoxia also injures vascular endothelial cells, breaking down the tight junctions of the microvascular barrier and inducing capillary leak syndrome, where protein-rich plasma escapes into the interstitial spaces, compounding intravascular volume depletion.

If decompensated shock persists without effective, aggressive volume and hemostatic resuscitation, it transitions inexorably into irreversible shock. At this terminal stage, profound widespread cellular necrosis, microvascular paralysis, and severe systemic metabolic acidosis cause complete loss of peripheral vascular tone. Arteriolar sphincters, previously constricted by catecholamines, relax completely due to local accumulation of vasoactive metabolites such as histamine, bradykinin, and adenosine, while venules remain constricted. Blood pools massively in dilated capillary beds, causing stagnation, microvascular thrombosis, and irreversible loss of effective circulating volume. The heart experiences severe ischemic myocardial depression, further dropping cardiac output. The patient enters multi-organ dysfunction syndrome, characterized by acute tubular necrosis and acute renal failure, acute respiratory distress syndrome due to non-cardiogenic pulmonary edema and alveolar injury, hepatic dysfunction, hypoxic-ischemic encephalopathy, and fatal cardiac arrest refractory to exogenous vasopressors and fluid administration.

A fundamental concept in the critical care management of severe hemorrhagic shock is the prevention and aggressive treatment of the lethal triad of trauma, composed of hypothermia, metabolic acidosis, and coagulopathy. Each component of this triad directly amplifies the severity of the others, creating a self-reinforcing, deadly physiological spiral. Hypothermia, defined as a core body temperature dropping below thirty-five degrees Celsius, develops rapidly in hemorrhaging obstetric patients due to rapid infusion of unwarmed intravenous fluids and stored blood products, heat loss from exposed abdominal cavities during laparotomy, reduced metabolic heat production from hypoperfused tissues, and environmental exposure in delivery suites. Hypothermia exerts a devastating inhibitory effect on the enzymatic coagulation cascade; key clotting enzymes, including the prothrombinase complex and factor VIIa, suffer a progressive drop in activity at lower temperatures, while platelet adhesion and aggregation are markedly impaired. Below thirty-three degrees Celsius, clotting kinetics deteriorate to a degree equivalent to severe factor deficiency, regardless of circulating clotting factor levels.

Metabolic acidosis, resulting from accumulation of lactic acid secondary to tissue anaerobic metabolism and worsened by chloride-rich resuscitation fluids like normal saline, further impairs the coagulation system. A drop in arterial pH below seven point three zero alters the tertiary structure of essential coagulation proteins, severely inhibiting thrombin generation and reducing the rate of fibrin polymerization. At a pH of seven point one zero, the activity of factor Xa/Va complexes drops by over fifty percent, and fibrinogen conversion is severely depressed. Acidosis also decreases vascular responsiveness to both endogenous and exogenous catecholamines, worsening refractory vasodilation and hypotension. Coagulopathy, the third arm of the triad, arises from a combination of direct hemorrhagic loss of factors, dilutional loss from excessive administration of crystalloid or colloid resuscitative fluids, consumptive loss via disseminated intravascular coagulation, and hypothermia/acidosis-induced enzyme inhibition. Unchecked, the lethal triad transforms manageable hemorrhage into uncontrollable, microvascular exsanguination.

The contemporary management of severe obstetric hemorrhagic shock has undergone a major paradigm shift, abandoning traditional crystalloid-heavy fluid strategies in favor of protocolized Damage Control Resuscitation. Historically, resuscitation guidelines recommended aggressive administration of large volumes of isotonic crystalloid solutions, such as zero point nine percent normal saline or lactated Ringer's solution, using a three-to-one volume replacement rule for every unit of blood lost. However, modern critical care research has established that high-volume crystalloid resuscitation causes severe dilutional coagulopathy by rapidly diluting remaining circulating platelets and coagulation factors, disrupts fragile early clot formations by abruptly increasing hydrostatic capillary pressure, worsens hypothermia through the infusion of room-temperature fluids, and induces tissue edema and abdominal compartment syndrome. Damage control resuscitation prioritizes the early, aggressive restriction of crystalloids, recommending that total crystalloid infusion be strictly limited to less than one to two liters prior to blood product availability.

Central to damage control resuscitation is the early activation of a protocolized Massive Transfusion Protocol. A massive transfusion is classically defined as the replacement of a patient's total blood volume within twenty-four hours, the administration of more than ten units of packed red blood cells within twenty-four hours, or the acute replacement of more than fifty percent of total blood volume within three hours. In modern obstetric emergency care, massive transfusion protocols are triggered rapidly using validated clinical criteria, such as an elevated Shock Index—calculated as heart rate divided by systolic blood pressure—where a value exceeding one point zero to1 point two indicates severe occult shock and high risk of massive blood requirement. The core component of a massive transfusion protocol is the rapid, continuous delivery of balanced, fixed-ratio blood product packs directly from the blood bank to the bedside, maintaining a empirical one-to-one-to-one ratio of packed red blood cells, fresh frozen plasma, and platelets, effectively mimicking the administration of warm whole blood.

The rationale for balanced empirical fixed-ratio transfusion is to prevent the early development of dilutional and consumptive coagulopathy by simultaneously replacing oxygen-carrying capacity, plasma coagulation factors, and platelets from the onset of resuscitation. Packed red blood cells restore intravascular volume and hemoglobin concentration, maintaining oxygen delivery to hypoperfused tissues; the target hemoglobin concentration during active resuscitation is maintained between seven and nine grams per deciliter. Fresh frozen plasma provides essential clotting factors and plasma volume, while platelet concentrates maintain cellular primary hemostasis. As soon as point-of-care viscoelastic testing results or standard laboratory coagulation parameters become available, resuscitation transitions rapidly from empirical fixed-ratio packs to targeted, goal-directed therapy, using targeted infusions of fibrinogen concentrate or cryoprecipitate, prothrombin complex concentrates, and specific platelets to correct identified hemostatic deficits precisely.

In addition to blood component administration, comprehensive damage control resuscitation incorporates several critical supportive and pharmacological interventions. Maintaining patient normothermia is imperative; all intravenous fluids and blood products must be infused through high-capacity fluid warmers at forty-two degrees Celsius, convective forced-air warming blankets must cover the patient, and the operating room or delivery suite temperature should be increased. Hypocalcemia, a frequent and dangerous complication of massive transfusion resulting from the chelation of circulating ionized calcium by the citrate preservative present in stored blood products and plasma, must be aggressively corrected. Ionized calcium plays a vital role in both myocardial contractility and multiple steps of the enzymatic coagulation cascade; levels should be continuously monitored using arterial blood gas analysis and maintained strictly above one point one to one point two millimoles per liter through frequent intravenous administration of calcium chloride or calcium gluconate.

While intravascular volume restoration remains the absolute priority in hemorrhagic shock, judicious deployment of vasoactive medications may be required when profound hypotension threatens immediate cardiac arrest despite ongoing volume infusion. Vasoactive agents, such as norepinephrine or phenylephrine, should be utilized primarily as a temporary bridge to maintain a minimum mean arterial pressure of sixty-five millimeters of mercury—ensuring basic perfusion to the brain and coronary arteries—while volume deficits and surgical bleeding are actively addressed. However, excessive or unguided reliance on potent alpha-adrenergic vasopressors without adequate fluid resuscitation must be avoided, as it causes severe microvascular vasospasm, exacerbates tissue hypoperfusion, and further reduces uterine perfusion. Once surgical, endovascular, or mechanical hemostasis is achieved and tissue hypoperfusion is reversed, resuscitation efforts transition smoothly toward post-stabilization intensive care monitoring, focused on mitigating secondary inflammatory complications, managing acute kidney injury, preventing venous thromboembolism via timely mechanical and pharmacological prophylaxis, and supporting recovery.

Conclusion

The management of acute traumatic, hemorrhagic, and coagulopathic emergencies in obstetrics represents one of the most demanding domains within contemporary medicine. Soft tissue birth canal trauma, postpartum hemorrhage, disseminated intravascular coagulation, and hemorrhagic shock are not isolated clinical entities, but rather interconnected nodes along a dangerous pathophysiological continuum. A mechanical disruption of the birth canal or an uncorrected failure of myometrial tone can trigger massive volume loss, initiating a cascade that leads to tissue-factor-mediated consumption coagulopathy, profound metabolic acidosis, microvascular collapse, and multi-organ failure. Reversing this trajectory requires an integrated clinical approach that combines meticulous anatomical repair, rapid pharmacological intervention, point-of-care coagulation diagnostic profiling, and balanced damage control resuscitation.

The evolution of modern obstetric critical care highlights the vital importance of replacing historical, reactive resuscitation strategies with standardized, protocol-driven emergency frameworks. The early administration of tranexamic acid, the implementation of balanced massive transfusion protocols using fixed-ratio blood components, the routine deployment of point-of-care viscoelastic testing for goal-directed hemostatic correction, and the utilization of conservative mechanical and surgical devascularization techniques have significantly improved maternal survival rates. Ultimately, minimizing maternal mortality and severe morbidity from these catastrophic emergencies depends on early clinical recognition, seamless communication across multidisciplinary obstetric, anesthetic, surgical, and critical care teams, and an unwavering commitment to evidence-based resuscitative protocols.

References

1.     Brenner, A., Ker, K., Shakur-Still, H., & Roberts, I. (2019). Tranexamic acid for post-partum haemorrhage: What, who and when. Best Practice & Research Clinical Obstetrics & Gynaecology, 61, 66–74. https://doi.org/10.1016/j.bpobgyn.2019.04.005 Cited by: 92

2.     American College of Obstetricians and Gynecologists. (2017). ACOG Practice Bulletin No. 183: Postpartum hemorrhage. Obstetrics & Gynecology, 130(4), e168–e186. https://doi.org/10.1097/AOG.0000000000002351

3.     Natalini, D. (2025). Viscoelastic hemostatic assays in the management of trauma and acute coagulopathy. Journal of Clinical Medicine, 15(1), 12. https://doi.org/10.3390/jcm15010012 Cited by: 7

4.     WOMAN Trial Collaborators. (2017). Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): An international, randomised, double-blind, placebo-controlled trial. The Lancet, 389(10084), 2105–2116. https://doi.org/10.1016/S0140-6736(17)30638-4

5.     World Health Organization. (2018). WHO recommendations: Uterotonics for the prevention of postpartum haemorrhage. World Health Organization.

6.     D'Alton, M. E., Main, E. K., Menard, M. K., & Shields, L. E. (2014). The National Partnership for Maternal Safety: Consensus bundle on obstetric hemorrhage. Anesthesia & Analgesia, 119(5), 1185–1194. https://doi.org/10.1213/ANE.0000000000000461

7.     Ekelund, C. K., & Jørgensen, F. S. (2020). Genital tract lacerations and puerperal hematomas: Diagnosis and management. Acta Obstetricia et Gynecologica Scandinavica, 99(8), 980–991. https://doi.org/10.1111/aogs.13840

8.     Levi, M., & Ten Cate, H. (1999). Disseminated intravascular coagulation. New England Journal of Medicine, 341(8), 586–592. https://doi.org/10.1056/NEJM199908193410807

9.     Spahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., Samama, C. M., Vincent, J. L., & Rossaint, R. (2019). The European guideline on management of major bleeding and coagulopathy following trauma: Fifth edition. Critical Care, 23(1), 98. https://doi.org/10.1186/s13054-019-2347-3

10.  Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A. B., Daniels, J., Gülmezoglu, A. M., Temmerman, M., & Alkema, L. (2014). Global causes of maternal death: A WHO systematic analysis. The Lancet Global Health, 2(6), e323–e333. https://doi.org/10.1016/S2214-109X(14)70227-X

11.  Collins, P. W., Lilley, G., Bruynseels, D., Laurent, D., Cannings-John, R., Rees, A., Alvarez, M., Hall, J. E., Thomas, J., & Weeks, A. (2014). Fibrin-based clot strength, fibrinogen concentration and blood loss after delivery. British Journal of Anaesthesia, 113(1), 97–109. https://doi.org/10.1093/bja/aee120

12.  Holcomb, J. B., Tilley, B. C., Baraniuk, S., Fox, E. E., Wade, C. E., Podbielski, J. M., Del Junco, D. J., Brasel, K. J., Bulger, E. M., Callcut, R. A., Cohen, M. J., Cotton, B. A., Fabian, T. C# Emergency Obstetric Dynamics: A Comprehensive Analysis of Birth Canal Traumas, Postpartum Hemorrhage, Disseminated Intravascular Coagulation, and Hemorrhagic Shock